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Prostate-specific antigen (PSA) is a protease produced in the prostate that cleaves insulin-like growth factor binding protein-3 and
other proteins. Production is mediated by the androgen receptor (AR) binding to the androgen response elements (ARE) in the
promoter region of the PSA gene. Studies of a single nucleotide polymorphism (PSA  158 G/A, rs266882) in ARE1 of the PSA gene
have been conflicting for risk of prostate cancer and effect on plasma PSA levels. In this nested case–control analysis of 500 white
cases and 676 age- and smoking-matched white controls in the Physicians’ Health Study we evaluated the association of rs266882
with risk and survival of prostate cancer and prediagnostic total and free PSA plasma levels, alone or in combination with AR CAG
repeats. We used conditional logistic regression, linear regression and Cox regression, and found no significant associations between
rs266882 (GG allele vs AA allele) and overall prostate cancer risk (RR¼1.21, 95% confidence intervals (CI): 0.88–1.67) or prostate
cancer-specific survival (RR¼0.94, 95%CI: 0.56–1.58). Similarly, no associations were found among high grade or advanced stage
tumours, or by calendar year of diagnosis. There was no significant association between rs266882 and baseline total or free PSA
levels or the AR CAG repeats, nor any interaction associated with prostate cancer risk. Meta-analysis of 12 studies of rs266882 and
overall prostate cancer risk was null.
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Prostate-specific antigen (PSA) is a protease produced primarily in
the prostate and has widely been used as a diagnostic marker of
prostate cancer since the early 1990s (Cohen et al, 1994).
Production of PSA is mediated through binding of the androgen
receptor (AR) to androgen response elements (ARE) in the
promoter region of the PSA gene (Janne et al, 1993). Given the
importance of PSA as a prostate cancer biomarker, regulation of
the gene is of great interest.
A single nucleotide polymorphism in ARE1 (PSA  158 G/A) of
the PSA gene (rs266882), identified in 1999 (Rao and Cramer,
1999), has been the focus of numerous studies of prostate cancer
risk. ARE1 is the primary binding site in the promoter of the PSA
gene, and the A to G substitution of rs266882 may affect the
binding affinity of the AR and subsequently affect transcript levels
of the PSA gene.
An initial case–control study found that men with the
homozygous variant GG genotype were at increased risk of
advanced prostate cancer (Xue et al, 2000). Subsequent
studies on this polymorphism have been conflicting, however,
with some reporting an increased risk of prostate cancer or
higher PSA levels associated with the G allele (Chiang et al, 2004;
Binnie et al, 2005; Schatzl et al, 2005), increased risk with the
A allele (Gsur et al, 2002; Medeiros et al, 2002; Lai et al, 2007)
or no association with risk (Xu et al, 2002; Rao et al, 2003;
Wang et al, 2003; Severi et al, 2006; Sieh et al, 2006). Among
healthy men, the AA genotype was associated with higher serum
PSA levels compared with those carrying a G allele (Xue et al,
2001). Moreover, the effect of the variant differed as a function
of CAG repeat length in the AR gene (Xue et al, 2001). However,
the finding with the G/A variant and PSA levels has not
been confirmed (Severi et al, 2006). The one study that examined
the polymorphism with prostate cancer survival found no
significant association with cancer-specific mortality (Severi
et al, 2006).
To address the disparity of findings of this SNP, we performed a
large nested case–control study in the Physicians’ Health Study
(PHS) to evaluate the rs266882 polymorphism in prostate cancer.
We examined associations with risk, survival and prediagnostic
baseline plasma PSA levels, alone and in combination with AR
CAG repeats. Additionally, we performed a meta-analysis of
published studies that have examined the rs266882 polymorphism
and overall prostate cancer risk.
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sMATERIALS AND METHODS
Study population
The PHS is a randomised double-blind trial of aspirin and
b-carotene among 22071 US male physicians, aged 40–84 years in
1982; none had a cancer diagnosis at baseline (1989). The current
study was nested among the subset of 14916 participants, who
provided plasma and whole blood prior to randomisation. Men
were followed for incident cancer, including prostate, and all cases
are confirmed through medical record review. Men with prostate
cancer are followed to collect detailed information on disease
progression and development of metastases. Cause of death is
confirmed by review of death certificate and pertinent medical
records. Collection of additional study characteristics including
age at enrolment, blood collection and processing, stage classifica-
tion and clinical follow-up were described earlier (Gann et al,
1996).
We included in the study 500 cases diagnosed through 1995.
Cases were matched (1:1, 1:2 or 1:3) on age (±1 year when
feasible, but up to ±5 years for older men) and smoking status
(current, former and never) to controls selected at random from
among men free from diagnosed prostate cancer at the time the
case was diagnosed. A total of 676 controls were included. All men
provided informed consent, and the protocol was approved by the
Institutional Review Board at Partners Healthcare.
Laboratory analysis
Using baseline plasma samples, we measured total and free PSA
levels by a double-antibody radioimmmunoassay using rabbit
polyclonal anti-PSA on the basis of competitive binding as
described earlier (Gann et al, 1995). The rs266882 polymorphism
was assayed on extracted DNA according to the protocol described
by Xue et al (2000). Briefly, the alleles of the G/A polymorphism at
position  158 in the promoter region of the PSA gene were
amplified and the three possible genotypes were distinguished by
cutting with the NheI restriction enzyme. The AR gene CAG repeat
length was determined by running the PCR-amplified fragments
on a denaturing polyacrylamide gel with automated fluorescence
detection of the fragments and sizing by Genescan (Giovannucci
et al, 1997).
Statistical analysis
To limit the potential for population stratification, we restricted
the analysis to white men (94% of PHS cohort is white). Hardy–
Weinberg equilibrium of allelic frequency was tested by a goodness
of fit w
2-test. We calculated odds ratios as an estimate of relative
risk ratios and 95% confidence intervals (CI) using conditional
logistic regression, matched on age and smoking status, to evaluate
the association between the rs266882 polymorphism and prostate
cancer risk. We stratified the analysis further according to tumour
grade (low grade: Gleason 2–6 or well differentiated; moderate
grade: Gleason 7 or moderately differentiated; high grade: Gleason
8–10 or poorly differentiated), stage (T1/T2 or T3/T4) and
calendar year of diagnosis (1982–1992 or 1992–1995). The
following number of cases and matched controls (cases; controls)
for each subgroup: low grade (265; 360), moderate grade
(137; 180), high grade (83; 113), localized: T1/T2 (303; 409), or
advanced: T3/T4 (156; 214) tumour stage, diagnosed 1982–1992
(357; 530) and diagnosed 1992–1995 (143; 146).
Additionally, we assessed whether the association of rs266882
genotype and prostate cancer risk differed according to categorical
pre-diagnostic PSA levels (total PSA: o4ngml
 1, X4ngml
 1; free
PSA: o15%, 15–24%, X25%) or number of AR CAG repeats
(tertiles, 7–20, 21–23 and 24–39) using likelihood ratio tests.
We used time to event analyses to evaluate the rs266882
polymorphism and cancer-specific survival. Person–time was
calculated from date of cancer diagnosis to prostate cancer death
or censored at time of death from other causes or end of follow-up
(31 March 2007). We used Cox proportional hazard models to
calculate hazard ratios and 95% CI, adjusted for aggressive disease
(i.e., stage T3/T4 or high grade), age at diagnosis and date of
diagnosis (pre/post 1992).
Linear regression was used to estimate the association among
PSA levels (natural log transformed) with rs266882 genotype,
separately for cases and controls. An interaction with AR CAG
repeats was evaluated to determine if the effect of rs266882
genotype differed according to AR CAG repeat length. The SAS
Statistical Software (Version 9.1) was used for these analyses.
We conducted a meta-analysis of 12 published studies that have
evaluated the association between the rs266882 polymorphism and
prostate cancer risk (Xue et al, 2000; Gsur et al, 2002; Medeiros
et al, 2002; Wang et al, 2003; Chiang et al, 2004; Binnie et al, 2005;
Cicek et al, 2005; Salinas et al, 2005; Severi et al, 2006; Sieh et al,
2006; Lai et al, 2007). To standardise comparisons across the
studies, we calculated odds ratios and overall prostate cancer risk
comparing the rs266882 GG vs AA genotypes and GA vs AA
genotypes. Inverse variance weighting with a random effects model
was used to create a summary estimate using the statistical
package Stata (StataCorp, 2003).
RESULTS
Genotype data was available for 500 cases and 676 controls. Among
cases, mean age at diagnosis was 68 years, 17% had poorly
differentiated tumours (3% missing) and 31% were advanced
tumour stage at diagnosis (8% missing) (Table 1). The majority of
cases (71%) were diagnosed before 1992, prior to widespread PSA
screening.
The rs266882 genotype distribution among controls (GG: 25%,
GA: 47% and AA: 28%) was similar to other studies of white men
(Xue et al, 2000; Cicek et al, 2005; Salinas et al, 2005; Sieh et al,
2006) and was in Hardy–Weinberg equilibrium (P¼0.18).
Controlling for matching factors, there was no evidence of an
Table 1 Characteristics of prostate cancer cases in the Physicians’ Health
Study, incidence 1982–1995 and survival 1982–2007
Cases (N¼500)
Mean age at baseline (±s.d.) 61.2 (7.6)
Mean age at diagnosis (±s.d.) 68.4 (6.8)
Grade at diagnosis (%)
a,b
Low grade 265 (53.0)
Moderate grade 137 (27.4)
High grade 83 (16.6)
Tumour stage at diagnosis (%)
c
T1/T2 303 (60.6)
T3/T4 156 (31.2)
PSA era (%)
Before 1992 357 (71.4)
1992 or after 143 (28.6)
Died from prostate cancer (%)
Died 111 (22.2)
Survived 389 (77.8)
PSA¼Prostate-specific antigen.
a15 cases missing grade.
bLow-grade disease:
Gleason 2–6 or well differentiated; Moderate grade: Gleason 7 or moderately
differentiated; High grade: Gleason 8–10 or poorly differentiated.
c41 cases missing
stage.
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Moreover, we found no association between the rs266882 genotype
and cancer risk when we stratified within tumour grade or stage, or
among those diagnosed pre/post PSA era (Table 2).
As shown earlier in Gann et al (2002), pre-diagnostic total and
free PSA levels measured in baseline blood were significantly higher
among cases compared with controls (Table 3). Using age-adjusted
linear regression, we found no significant association between the
rs266882 genotype and levels of total or free PSA among either
cases or controls. Similarly, we did not see a difference in total
prostate cancer risk when the analysis was stratified by rs266882
genotype and total plasma PSA level (P for interaction B0.41) or
free PSA level (P for interaction B0.70).
An earlier study within the PHS cohort examined a trinucleotide
CAG repeat polymorphism in AR. Shorter AR CAG repeats, which
are associated with greater transactivation of the AR, were
associated with higher risk of advanced prostate cancer compared
with longer AR CAG repeats (Giovannucci et al, 1997). In this
study, we examined whether the association between the rs266882
genotype and prostate cancer risk or baseline PSA levels was
modified by AR CAG repeat length. However, there was no
evidence of association between the rs266882 genotype and total
prostate cancer risk among men with long or short CAG repeats. In
addition, there was no evidence of modification by AR CAG repeat
length on associations between the rs266882 genotype on total
plasma PSA levels (P-value for interaction: controls, P¼0.80; cases,
P¼0.25) and free PSA levels (controls, P¼0.30; cases, P¼0.96).
Among the 500 men with prostate cancer, 111 men died of their
disease. The median survival time between diagnosis and prostate
cancer-specific death was 13.5 years (range: o1–24.3 years). We
found no association between the rs266882 genotype and prostate
cancer survival (Table 4).
Figure 1 presents the estimates from each of the 12 studies of the
rs266882 genotype and prostate cancer risk, and the summary
odds ratios from the meta-analysis. There was no evidence of
an association between the GG (OR¼0.96, 95% CI: 0.77, 1.20)
(Figure 1) or GA (OR¼0.92, 95% CI: 0.82, 1.03) genotypes
compared with AA. Sensitivity analyses were performed by
restricting the meta-analysis to eight studies conducted among
predominantly white populations that reported similar rs266882
genotype distribution among controls. These analyses produced
results similar to the full meta-analysis of 12 studies.
DISCUSSION
In this large prospective study, we comprehensively assessed the
relation of the ARE1 (PSA  158 G/A) polymorphism (rs266882
genotype) and prostate cancer risk, survival and pre-diagnostic
plasma PSA levels. We found no association between the PSA
polymorphism and cancer risk, overall or by grade, stage or
calendar year of diagnosis. Similarly, the rs266882 genotype was
not associated with cancer-specific survival. Finally, there was no
association between the rs266882 genotype and PSA plasma levels
among cases or controls. There were no significant interactions of
the rs266882 genotype with PSA plasma level or AR CAG repeat
length for any of the outcomes examined.
Given the importance of PSA, regulation of its production is of
biological and clinical importance. For example, PSA cleaves
insulin-like growth factor binding proteins resulting in local
release of IGF-1 (Cohen et al, 1994), which has been positively
associated with prostate cancer risk (Chan et al, 1998; Stattin et al,
2000). PSA has also been demonstrated to activate the small latent
form of transforming growth factor-b2 (TGF-b2) (Dallas et al,
2005), one of the isoforms of TGF-b, a potent growth factor that
acts as a tumour enhancer once cancer cells have become
Table 2 Odds ratios
a and 95% confidence intervals of association between ARE1 (PSA  158 G/A) genotype and prostate cancer risk, overall and by
tumour grade,
b stage and calendar year of diagnosis
PSA genotype
N (cases/controls) AA GA GG
Total prostate cancer 500/676 1.00 (Ref) 1.00 (0.76–1.33) 1.21 (0.88–1.67)
Tumour grade
b
Low grade 265/360 1.00 (Ref) 0.88 (0.61–1.29) 1.25 (0.81–1.93)
Moderate grade 137/180 1.00 (Ref) 1.11 (0.63–1.95) 1.41 (0.75–2.65)
High grade 83/113 1.00 (Ref) 1.39 (0.63–3.08) 1.22 (0.51–2.90)
Tumour stage
T1/T2 303/409 1.00 (Ref) 1.01 (0.71–1.46) 1.33 (0.89–1.99)
T3/T4 156/214 1.00 (Ref) 0.90 (0.53–1.51) 0.86 (0.45–1.62)
Diagnosis date
Before 1992 357/530 1.00 (Ref) 0.94 (0.67–1.31) 1.05 (0.72–1.55)
1992 or after 143/146 1.00 (Ref) 1.14 (0.67–1.94) 1.69 (0.92–3.08)
PSA¼Prostate-specific antigen. Physicians’ Health Study, 1982–1995.
aOdds ratios are controlled for age and smoking by matching.
bLow-grade disease: Gleason 2–6 or well
differentiated; Moderate grade: Gleason 7 or moderately differentiated; High grade: Gleason 8–10 or poorly differentiated.
Table 3 Median and 25th, 75th percentile (IQR) distributions of baseline
total and free PSA levels among prostate cancer cases and controls
according to PSA ARE1  158 G/A genotype
a
Total PSA Free PSA
PSA genotype n
b Median (IQR) Median (IQR)
Cases
AA 83 2.4 (1.3, 5.0) 0.4 (0.3, 0.7)
GA 159 2.7 (1.5, 5.6) 0.5 (0.3, 0.8)
GG 93 2.7 (1.6, 5.9) 0.5 (0.3, 0.9)
Controls
AA 172 1.1 (0.7, 1.9) 0.3 (0.2, 0.4)
GA 278 1.1 (0.7, 2.0) 0.3 (0.2, 0.5)
GG 139 1.0 (0.6, 2.1) 0.3 (0.2, 0.5)
PSA¼Prostate-specific antigen. Physicians’ Health Study, 1982–1995.
aAge-adjusted
estimates for effect of PSA genotypes on total or free PSA from linear regression
models were all non-significant at the a¼0.05 level.
bNumber of cases and controls
were the same for total and free PSA with the exception of cases/GA allele/free PSA,
n¼158.
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Activation of TGF-b2 by PSA may potentially contribute to the
formation of osteoblastic lesions in bone metastatic prostate
cancer (Dallas et al, 2005).
Accordingly, numerous investigators have examined the function
of the rs266882 polymorphism in PSA regulation alone or in
combination with other genes, with contradictory results. An initial
relatively small case–control study of non-Hispanic white men (57
cases, 156 controls) reported a positive association of the GG allele
of rs266882 with a three-fold risk of advanced cancer (Xue et al,
2000). Subsequent studies also reported increased risk of prostate
cancer with the G allele in Taiwan (122 cases, 84 controls)(Chiang
et al, 2004) and Scotland (97 cases, 144 controls)(Binnie et al, 2005).
A larger sibling-based case–control study (439 cases, 479 controls)
in a predominantly white American population found the GG allele
associated with risk of non-aggressive disease (Cicek et al, 2005). In
contrast, a large case–control study of 99% Caucasian Australians
(821 cases, 734 controls) found a significant association for the
G allele with stage III to IV tumours, but not for overall prostate
cancer (Severi et al, 2006).
Conversely, other studies found an association between the
A allele and increased risk of prostate cancer (Gsur et al, 2002;
Medeiros et al, 2002; Lai et al, 2007). A case control study of
Portuguese men (151 cases, 127 controls) found a three-fold
increased risk for men less than 67 years with the AA allele
(Medeiros et al, 2002). Similarly, a larger study of Australian
Caucasian men (209 cases, 223 controls) found a three-fold risk of
prostate cancer with the AA allele (Lai et al, 2007).
Several studies, including one in Japanese men (300 cases, 216
BPH controls, 266 controls) (Wang et al, 2003) and a predominantly
(B95%) white American population (591 cases, 538 controls)
(Salinas et al,2 0 0 5 ) ,a sw e l la st h ep r e s e n ts t u d y ,f o u n dn os i g n i f i c a n t
association between the PSA polymorphism and risk of prostate
cancer. Although, our own study cannot rule out small relative risks,
taken together with our meta-analysis of the 12 studies suggests that
there is no overall effect of the variant on prostate cancer risk.
Only one published study has examined the rs266882 variant
with survival of prostate cancer (Severi et al, 2006). The average
follow-up was 8.2 years, with 68 deaths. Our study was consistent
with the Severi et al (2006) study in finding no significant
association with the rs266882 genotype and risk of dying from
prostate cancer.
It has been hypothesised that the rs266882 polymorphism may
be associated with serum levels of PSA through higher binding
affinity of the ARE1 with either the A or G allele. Results of such
studies also have been contradictory. Among healthy controls (PSA
levels o4ngml
 1), higher serum PSA levels were statistically
significantly associated with AA genotype when all ethnic groups
were combined, but not for any of the ethnic groups individually,
suggesting population stratification may be a possibility for this
Table 4 Hazard ratios and 95% confidence intervals of ARE1 (PSA  158 G/A) genotype and prostate cancer-specific survival, overall and stratified by
grade
a, stage and calendar year of diagnosis
n PSA genotype
Cases Deaths AA GA GG
Overall survival
b 500 111 1.00 (Ref) 0.96 (0.61–1.51) 0.94 (0.56–1.58)
Tumour grade
c
Low grade 265 29 1.00 (Ref) 0.59 (0.26–1.33) 0.39 (0.14–1.10)
Moderate grade 137 32 1.00 (Ref) 0.97 (0.43–2.21) 0.73 (0.27–1.96)
High grade 83 43 1.00 (Ref) 1.42 (0.57–3.53) 1.81 (0.70–4.74)
Tumour stage
c
T1/T2 303 37 1.00 (Ref) 0.81 (0.38–1.72) 0.67 (0.27–1.65)
T3/T4 156 68 1.00 (Ref) 1.13 (0.62–2.05) 1.07 (0.54–2.11)
PSA¼Prostate-specific antigen. Physicians’ Health Study, 1982–2007.
aLow-grade disease: Gleason 2–6 or well differentiated; Moderate grade: Gleason 7 or moderately
differentiated; High grade: Gleason 8–10 or poorly differentiated.
bHazard ratios controlled for aggressive disease (i.e., stage T3/T4 or high grade), age at diagnosis and date of
diagnosis (pre/post 1992).
cHazard ratios controlled for age at diagnosis and date of diagnosis (pre/post 1992).
Odds Ratio
0.2 0.5 1 2 5
Combined
Chiang
Xue
Wang
Binnie
Medeiros
Lai
Gsur
Sieh
Cicek
Salinas
Jesser
Severi
Study Cases Controls
nn
Severi 814 713
Jesser 500 676
Salinas 557 523
Cicek 439 479
Sieh 193 391
Lai 209 223
Gsur 190 190
Medeiros 151 127
Binnie 97 144
Wang 300 266
Xue 57 156
Chiang 122 84
Figure 1 Meta-analysis of 12 studies of the association between rs266882 GG genotype compared with AA genotype and overall prostate cancer risk.
Individual and random effects, summary odds ratios and 95% confidence intervals (CI). The shaded squares and horizontal lines indicate the study-specific
odds ratio and 95% CI for the rs266882 GG genotype compared with the AA genotype. The area of the shaded square is proportional to the inverse of the
sum of the between studies variance and the study-specific variance. The diamond is the summary odds ratio and 95% CI.
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levels o4ngml
 1, men with the AA genotype had a 28% higher level
of PSA than men with the GG genotype (Salinas et al, 2005). Two
studies of healthy controls with PSA levels o4ngml
 1 (Rao and
Cramer, 1999; Wang et al, 2003) and one with PSA o9ngml
 1
(Severi et al, 2006) reported no association of this genotype with
serum PSA level. These null results were consistent with our findings.
AR regulates PSA expression by binding androgen response
elements. Some studies of AR, including ours, found shorter CAG
repeats associated with increased expression of AR and with higher
risk of advanced prostate cancer compared with longer CAG
repeats (Giovannucci et al, 1997). Therefore, the potential
interaction of the rs266882 genotype with CAG repeats in the AR
is of interest. Xue et al (2000) reported a five-fold increased risk
for prostate cancer among white men with both a short CAG allele
and PSA genotype GG. In the full multi-ethnic cohort, Xue et al
(2001) also reported a significant interaction (0.049) with serum
PSA, which increased 7% with each decrease of one CAG among
those with the AA genotype for the PSA gene. Models were
adjusted for age and ethnicity, however residual confounding by
ethnicity in this very diverse cohort could account for this
borderline significant finding. Four additional studies, as well as
the present, found no interaction between rs266882 genotype and
AR CAG length in relation to plasma PSA levels (Xu et al, 2002;
Rao et al, 2003; Salinas et al, 2005; Sieh et al, 2006).
The results of this large study with long-term and prospective
follow-up, taken together with earlier findings and the results of
the meta-analysis, add further support for the conclusion that the
rs266882 polymorphism is unrelated to prostate cancer risk,
survival or to plasma PSA levels.
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